Pancreatic Cancer Diagnostic Market - By Product, By Test Type, By Cancer Type, By End Use - Global Forecast, 2025 - 2034

Pancreatic Cancer Diagnostic Market Size

The global pancreatic cancer diagnostic market was estimated at USD 2.5 billion in 2024. The market is expected to grow from USD 2.7 billion in 2025 to USD 5 billion in 2034, growing at a CAGR of 7.2%, according to Global Market Insights Inc. The market is steadily growing, driven by the rising prevalence of pancreatic cancer, advancements in diagnostic technologies, increasing global healthcare spending, and greater awareness about the importance of early cancer detection.

Pancreatic cancer diagnostics involve a variety of methods and technologies designed to detect pancreatic cancer at different stages. These include advanced imaging technologies, biomarker assays, molecular diagnostics, and biopsy techniques, which play a critical role in confirming malignancy and guiding treatment plans. These tools are especially important because pancreatic cancer is often symptomless in its early stages and becomes highly dangerous when diagnosed late. Leading companies in this market include GE Healthcare, Siemens Healthineers, F. Hoffmann-La Roche, Thermo Fisher Scientific, and Koninklijke Philips. The market focuses on products such as imaging tools, biopsy instruments, liquid biopsy kits, tumor marker assays, and next-generation sequencing platforms. These innovations are aimed at improving diagnostic accuracy, enabling earlier detection, and supporting personalized treatment approaches.
 

The market grew from USD 2.1 billion in 2021 to USD 2.4 billion in 2023, largely due to increasing global healthcare investments. The growing number of pancreatic cancer cases and advancements in diagnostic technologies have significantly driven the adoption of these tools. Additionally, ongoing innovations such as AI-powered imaging, liquid biopsy techniques, and precision molecular diagnostics have enhanced diagnostic accuracy, reduced procedural risks, and improved patient outcomes. The healthcare sector’s focus on early disease detection, more efficient clinical workflows, and shorter hospital stays has further fueled the growth of the pancreatic cancer diagnostics market.
 

The growing number of pancreatic cancer cases is driving the market's growth. For example, data from the World Cancer Research Fund shows that in 2022, approximately 510,992 new cases of pancreatic cancer were diagnosed worldwide. This alarming statistic emphasizes the critical need for advanced diagnostic tools that can detect pancreatic cancer early and accurately, using minimally invasive methods. The combination of rising cases and advancements in imaging, molecular diagnostics, which is estimated to reach USD 40.4 billion by 2034, and biomarker testing is fueling the demand for better and more accessible diagnostic solutions.
 

Furthermore, the pancreatic cancer diagnostics market is seeing significant growth due to increased awareness about the importance of early cancer detection. This awareness is being driven by global campaigns, research funding, and policy initiatives. Organizations such as the Pancreatic Cancer Action Network (PanCAN) have been instrumental in raising awareness through public education, advocacy, and funding. In 2022, PanCAN invested USD 10.5 million to support research and development of early detection technologies. This funding reflects a growing commitment to improving diagnostic tools and outcomes for pancreatic cancer patients.
 

Pancreatic cancer diagnostics include a variety of medical tests, imaging technologies, and molecular tools designed to detect, confirm, and monitor the disease. These diagnostics are vital for identifying cancerous cells in the pancreas, determining the stage of the disease, and guiding treatment decisions effectively.
 

Pancreatic Cancer Diagnostic Market Trends

• Technological advancements are significantly reshaping the pancreatic cancer diagnostics market. Early detection has historically been challenging due to the disease’s asymptomatic progression and the pancreas’s deep anatomical location. Recent innovations are improving detection accuracy, speed, and accessibility, leading to better patient outcomes and expanding market opportunities.
   
• The integration of AI-powered imaging systems is a key development in this space. Companies such as Siemens Healthineers and GE Healthcare have introduced advanced CT and MRI scanners equipped with artificial intelligence algorithms. These systems enhance image resolution, automate lesion detection, and reduce scan times, offering superior diagnostic capabilities.
   
• For example, GE Healthcare’s SIGNA Champion 1.5T MRI Scanner is a cutting-edge imaging solution designed to enhance diagnostic precision in pancreatic cancer care. Equipped with AI-powered technologies such as AIR Recon DL and Sonic DL, the system delivers high-resolution images with reduced scan times.
   
• In addition, liquid biopsy technologies are gaining traction due to their non-invasive nature. These tests analyze circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomes from blood samples.
   
• For instance, Thermo Fisher Scientific’s TaqMan Liquid Biopsy dPCR Assays enable sensitive detection of ctDNA mutations, while QIAGEN’s QIAamp ccfDNA/RNA Kit supports dual analysis of cfDNA and cfRNA for comprehensive genetic profiling.
   
• Further, point-of-care diagnostic tools are emerging as vital solutions, particularly in low-resource settings. These compact systems enable rapid testing and immediate results, reducing diagnostic delays and improving access to care in underserved regions, thus driving market growth.
   

Pancreatic Cancer Diagnostic Market Analysis

Learn more about the key segments shaping this market

Download Free PDF

The global market was valued at USD 2.1 billion in 2021. The market size reached USD 2.5 billion in 2024, from USD 2.2 billion in 2022.
 

Based on the product, the pancreatic cancer diagnostic market is segmented into instruments and consumables. The consumables segment led this market in 2024, accounting for the highest market share because of its high demand for reagents and assay kits and the growing adoption of liquid biopsy and molecular testing techniques. This segment was valued at USD 1.4 billion in 2024 and is projected to reach USD 2.8 billion by 2034, growing at a CAGR of 7%.
 

This growth is due to the continuous need for repeat testing, rising adoption of personalized medicine, and the increasing use of consumables in advanced diagnostic techniques such as liquid biopsy, molecular profiling, and immunoassays. In comparison, the instruments segment, valued at USD 1.1 billion in 2024, is expected to grow to USD 2.2 billion by 2034, with a slightly higher CAGR of 7.5%, supported by continuous technological innovations, increasing adoption of AI-powered imaging systems, and rising demand for advanced diagnostic equipment in hospitals and diagnostic imaging centers.
 

• Reagents, assay kits, and sample preparation materials are crucial for pancreatic cancer diagnostics, ensuring consistent demand across clinical settings. These consumables support both imaging-based and molecular diagnostics, facilitating routine testing, biomarker analysis, and sample preparation.
   
• Moreover, these standardized consumables are compatible with various diagnostic platforms, streamlining laboratory workflows, reducing training needs, and ensuring consistent performance across diverse testing environments.
   
• For instance, Abbott’s ARCHITECT CA 19-9XR assay, a high-sensitivity immunoassay, quantitatively determines the CA 19-9 tumor marker, aiding in the detection and monitoring of pancreatic cancer. Its reliable performance and seamless integration into routine diagnostics bolster clinical decision-making and patient management.
   
• Furthermore, advanced diagnostic procedures such as liquid biopsies, PCR, and next-generation sequencing (NGS) increasingly rely on these consumables to detect genetic mutations, tumor markers, and circulating tumor DNA (ctDNA), driving market growth.
   

Based on the test type, the pancreatic cancer diagnostic market is segmented into imaging test, biopsy, blood test, and other test type. The imaging test segment accounted for the highest market share of 60.3% in 2024.
 

• Imaging tests, including CT scans and MRI, are vital in diagnosing pancreatic cancer. These modalities enable clinicians to visualize the pancreas, nestled deep in the abdomen and surrounded by other organs, providing detailed anatomical views without invasive procedures, crucial for initial diagnosis and staging.
   
• For example, Siemens’ MAGNETOM Vida, with AI-enhanced abdominal imaging, offers high-resolution scans swiftly and efficiently, excelling in visualizing intricate abdominal structures such as the pancreas for early cancer detection.
   
• Similarly, Philips’ Ingenia Elition 3.0T offers high-definition imaging with significantly shorter scan times, enhancing both patient comfort and diagnostic accuracy.
   
• Moreover, imaging tests also guide fine-needle aspiration biopsies and surgical planning. Techniques such as endoscopic ultrasound (EUS) and MRI accurately locate and assess tumor extent, ensuring precise sampling and reducing procedural risks. Such capabilities not only enhance diagnostic accuracy but also refine treatment planning and outcomes, propelling market growth.
   

Based on the cancer type, the pancreatic cancer diagnostic market is segmented into exocrine and endocrine. The exocrine segment accounted for the highest market share of 92.8% in 2024.
 

• The pancreatic cancer diagnostics segment is witnessing robust growth, fueled by the rising prevalence of exocrine pancreatic cancers, including adenocarcinoma, colloid carcinoma, adenosquamous carcinoma, and squamous cell carcinoma.
   
• For instance, the data from the National Institutes of Health (NIH) states that among these, pancreatic adenocarcinoma is the most common, accounting for approximately 85% of all exocrine pancreatic cancers. The increasing incidence of these cancer types is significantly accelerating the demand for advanced diagnostic solutions.
   
• Therefore, as the prevalence of exocrine pancreatic cancers such as adenocarcinoma, colloid carcinoma, adenosquamous carcinoma, and squamous cell carcinoma continues to rise, the demand for technologies that support early detection, accurate staging, and effective treatment planning is growing rapidly.
   
• Moreover, technological advancements are reshaping diagnostic workflows. Innovations such as AI-assisted imaging, cryo-biopsy techniques, and automated lesion detection are enhancing diagnostic accuracy, shortening turnaround times, and prioritizing patient safety and comfort. Such progress is catalyzing the adoption of advanced diagnostic devices, fueling the growth of the pancreatic cancer diagnostics market.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on end use, the pancreatic cancer diagnostic market is segmented into cancer research institutes, hospitals and clinics, diagnostic laboratories, and diagnostic imaging centers. In 2024, diagnostic imaging centers held the largest share of 34.5%.
 

• Diagnostic imaging centers, with their specialized focus on imaging technologies and efficient workflows, are pivotal to the pancreatic cancer diagnostics market.
   
• These centers are equipped with advanced modalities such as CT, MRI, and endoscopic ultrasound (EUS), which are essential for detecting and staging pancreatic cancer. Their ability to deliver high-resolution imaging and rapid turnaround times makes them the preferred choice for early diagnosis and follow-up assessments.
   
• Additionally, imaging centers leverage dedicated radiology teams, streamlined operations, and flexible scheduling to boost patient throughput and diagnostic efficiency. With the rising demand for minimally invasive and precise diagnostics, these centers are increasingly integrating AI-powered imaging platforms and automated lesion detection systems, further elevating diagnostic accuracy and patient outcomes.
   
• Additionally, the diagnostic laboratories segment, accounting for 29.4% market share in 2024, is playing an increasingly pivotal role in advancing patient outcomes. These laboratories are not only central to routine diagnostics but also actively support clinical trials and translational research.
   

Looking for region specific data?

Download Free PDF

North America dominated the global pancreatic cancer diagnostics market with the highest market share of 41.8% in 2024. The region has advanced healthcare infrastructure and a growing focus on early and accurate diagnosis. Further, there is an increasing prevalence of pancreatic cancer in the U.S. and Canada, thus propelling the growth of this market.
 

• The U.S. pancreatic cancer diagnostic market was valued at USD 779.9 million and USD 830.3 million in 2021 and 2022, respectively. In 2024, the market size reached USD 938.6 million from USD 882.4 million in 2023.
   
• The rising prevalence of pancreatic cancer in the U.S. is a significant driver of market growth.
   
• For instance, data from the World Cancer Research Fund indicates that in 2022, approximately 60,127 new cases of pancreatic cancer were reported annually in the U.S., with 31,598 cases among men and 28,529 among women, highlighting a notable increase in cases over the years.
   
• Therefore, as the number of pancreatic cancer cases increases, the demand for effective and technologically advanced diagnostic solutions for early detection and staging of cancer also rises, thereby accelerating market growth in the country.
   
• Additionally, the U.S. benefits from a streamlined regulatory approval process, high public awareness, and significant investments in research and development, which support the steady introduction of innovative diagnostic solutions.
   

Europe pancreatic cancer diagnostic market accounted for USD 749.3 million in 2024 and is anticipated to show lucrative growth over the forecast period.
 

• The rising prevalence of pancreatic cancer in the region, combined with increasing government initiatives to enhance healthcare infrastructure, is expected to drive market growth.
   
• Moreover, European governments are making substantial investments in healthcare infrastructure, further encouraging the adoption of diagnostic solutions in the region. For instance, member countries of the European Union (EU) have allocated over USD 11.7 billion (EUR 10 billion) for healthcare infrastructure investments between 2021 and 2027.
   

Germany pancreatic cancer diagnostic market is projected to experience steady growth between 2025 and 2034.
 

• The market in Germany is expanding steadily, driven by the rising incidence of pancreatic cancer and a strong healthcare infrastructure. For example, data from the World Cancer Research Fund shows that in 2022, approximately 21,869 new cases of pancreatic cancer were reported annually in Germany, with 10,970 cases among men and 10,899 among women, highlighting a significant increase in cases over the years.
   
• Germany is emerging as a global leader in pancreatic cancer diagnostics, particularly through its integration of minimally invasive biopsy technologies and advanced imaging modalities, supported by a robust healthcare infrastructure and public-private initiatives.
   

The Asia Pacific region is projected to be valued at USD 526.5 million in 2024 and is expected to reach USD 1.1 billion by 2034.
 

• The pancreatic cancer diagnostic market in the Asia Pacific region is expanding rapidly due to the growing burden of pancreatic cancer, rising health awareness, and continuous advancements in diagnostic solutions for pancreatic cancer.
   
• Countries such as China, India, and Japan are adopting advanced technology, driven by the growing demand for advanced diagnostic solutions and expanding access to healthcare services.
   
• Additionally, the rapid growth in the number of hospitals and diagnostic imaging centers, along with government policies aimed at improving diagnostic capabilities, is further contributing to the growth of the market in the region.
   

Japan pancreatic cancer diagnostic market is poised to witness lucrative growth between 2025-2034.
 

• Japan has one of the fastest-aging populations, which necessitates frequent health monitoring.
   
• The country’s aging demographic is a significant driver, with 29.1% of the population aged 65 and older as of 2023, according to Statista. This population is more prone to chronic diseases such as pancreatic cancer, which is boosting the adoption of diagnostic solutions.
   
• Government support and public awareness campaigns are expanding access to diagnostic tests, positioning Japan as a key player in the Asia Pacific pancreatic cancer management landscape.
   
• Furthermore, the efficient pancreatic cancer diagnostic capabilities of the country can be attributed to its very high density of imaging devices, such as CT scanners, significantly exceeding the average of other OECD countries. As per Statista, in 2024, Japan leads the number of computer tomography (CT) scanners with 119.81 systems per million population.
   

Brazil is experiencing significant growth in the Latin America pancreatic cancer diagnostic market, driven by the increasing burden of cancer incidences.
 

• The rising prevalence of pancreatic cancer is contributing to the growth of the market in the country. For instance, according to data from the World Cancer Research Fund (WCRF), in 2022, approximately 14,670 new cases of pancreatic cancer were reported annually.
   
• Additionally, there is growing awareness about the benefits of early disease detection and prevention, driven by public health initiatives and education campaigns encouraging individuals to undergo health check-ups. This trend is expected to foster market growth.
   

Saudi Arabia in the Middle East and Africa pancreatic cancer diagnostic market is expected to experience significant and promising growth from 2025 to 2034.
 

• The government of Saudi Arabia is significantly investing in healthcare infrastructure to incorporate advanced diagnostic solutions within hospital settings, aiming to provide the utmost care to individuals suffering from chronic conditions in the country.
   
• According to the Saudi Ministry of Health, in 2023, the government allocated around USD 50.4 billion for healthcare infrastructure and social development.
   
• Such investments are anticipated to enhance the accessibility and quality of medical services for individuals in the country, accelerating market growth.
   

Pancreatic Cancer Diagnostic Market Share

• The top five players, such as GE Healthcare, Siemens Healthineers, F. Hoffmann-La Roche, Koninklijke Philips, and Thermo Fisher Scientific, collectively held 59% of the total market share. These players are continuing to strengthen their positions through innovation, regulation, and strategic collaborations. Players are investing substantially in technology by introducing next-generation devices and biopsy tools by enhancing their precision, real-time imaging, and minimally invasive procedures.
   
• Thermo Fisher Scientific maintains its leadership in the pancreatic cancer diagnostics segment with its Oncomine platform. This platform integrates liquid biopsy assays and next-generation sequencing (NGS) to enable high-sensitivity detection of tumor DNA and RNA. The company is investing in compact sequencing systems, AI-enhanced bioinformatics, and low-input nucleic acid workflows to improve diagnostic accuracy and facilitate early-stage detection.
   
• Manufacturers are adopting value-based pricing strategies to penetrate cost-sensitive markets, particularly in emerging economies. Leading players are addressing clinical needs by launching AI-assisted platforms for pancreatic cancer screening. These platforms feature real-time molecular profiling, automated lesion detection, and integrated reporting tools, thereby expanding access to precision diagnostics in outpatient and decentralized care settings.
   
• Emerging trends in the pancreatic cancer diagnostics market include the development of minimally invasive liquid biopsy tools, AI-powered imaging systems, and workflow-integrated platforms designed for early detection and personalized oncology. Technologies such as circulating tumor DNA assays, endoscopic ultrasound with contrast enhancement, and radiomics-based AI models are improving diagnostic precision and accessibility.
   

Pancreatic Cancer Diagnostic Market Companies

Few of the prominent players operating in the pancreatic cancer diagnostic industry include:
 

• Abbott Laboratories
• Agilent Technologies
• Becton, Dickinson and Company
• Boston Scientific Corporation
• Canon
• Danaher Corporation
• Esaote
• F Hoffmann-La Roche
• GE Healthcare
• Hitachi
• Illumina
• Koninklijke Philips
• Myriad Genetics
• Olympus Corporation
• QIAGEN
• Siemens Healthineers
• Sysmex Corporation
• Thermo Fisher Scientific
  
   
• GE HealthCare

GE HealthCare has a strong global workforce of approximately 51,000 employees, which enables the company to drive innovation and deliver high-quality solutions.
 

• Koninklijke Philips

Koninklijke Philips has a robust geographical presence, which enables it to enhance its market reach. Koninklijke Philips operates in more than 100 countries, thus comprising a strong distribution network.
 

• Siemens Healthineers

Siemens Healthineers holds a significant share in the pancreatic cancer diagnostic market through its comprehensive product portfolio. Siemens Healthineers emphasizes R&D and product development, offering advanced imaging capabilities, ergonomic designs, and AI-powered diagnostic tools.
 

Pancreatic Cancer Diagnostic Industry News:

• In July 2024, Koninklijke Philips received FDA 510(k) clearance for its SmartSpeed Precise Dual AI software, enabling up to 3x faster MRI scans and 80% sharper images. This AI-powered solution enhances workflow efficiency and diagnostic accuracy across Philips’ 1.5T and 3.0T MRI systems, reinforcing its commitment to precision imaging and scalable diagnostics.
   
• In July 2024, Becton, Dickinson and Company partnered with Quest Diagnostics to co-develop flow cytometry-based companion diagnostics for cancer, including pancreatic cancer. This collaboration combines BD’s expertise in cytometry with Quest’s biomarker validation capabilities to advance personalized oncology through FDA-approved diagnostic solutions.
   

The pancreatic cancer diagnostic market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million and from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Instruments
• Consumables

Market, By Test Type

• Imaging test
  • CT scan
  • MRI
  • Ultrasound
  • PET
  • Other imaging tests 
• Biopsy
• Blood test
  • Liver function tests
  • Tumor markers
  • Other blood tests
• Other test types

Market, By Cancer Type

• Exocrine
  • Adenocarcinoma
  • Colloid carcinoma
  • Adenosquamous carcinoma
  • Squamous cell carcinoma 
• Endocrine

Market, By End Use

• Cancer research institutes
• Hospitals and clinics
• Diagnostic laboratories
• Diagnostic imaging centers

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE